Global Hypoxia Chamber Market, By Type (84 x 35 mm Plates, 27 x 60 mm Plates, 12 x 100 mm Plates, 12 x 96-well Plates, and 18 x 25 cm2 Flasks), By Application (Cell Culture Imaging, Drug Discovery, and Others), By End User (Biopharmaceutical Companies, Clinical Laboratories, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 59.9 million in 2020 and is expected to exhibit a CAGR of 7.7% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.
Launch of novel products is expected to drive the market growth during the forecast period. For instance, in May 2020, CytoSMART Technologies announced the launch of a new live-cell imaging system. The CytoSMART Lux2 Duo Kit offers a straightforward, cost-effective solution for researchers carrying out immediate side-by-side comparisons between cell cultures. The CytoSMART Lux2 – Duo Kit is a compact automated system, specifically designed to operate from within CO2 incubators and hypoxia chambers.
Global Hypoxia Chamber Market – Impact of Coronavirus (COVID-19) Pandemic
Several people infected by COVID-19 need hospitalized and require ventilator support. Key players in the market are supporting research and development of treatments for COVID-19. For instance, researchers operated at BioSpherix, Ltd., a cell culture and animal modeling equipment manufacturing company, working on increasing translatability of in vitro COVID-19 research to correct the discrepancy between oxygen conditions routinely provided for cell-based assays and O2 levels actually measured within the human body. In healthy pulmonary alveoli, oxygen levels are reported at around 12% O2. In pulmonary blood, oxygen tensions exist over the 5-12% O2 range. In pathologic situations such as COVID-19, where air exchange is compromised due to pneumonia or ARDS, tissue oxygen levels will be far lower. Both, physiologic oxygen (physioxia) and pathophysiologic hypoxia occur at levels far below those assessed for room air (21% O2).
Why cell culture O2 levels impact COVID-19 data relevance:
- ACE2 Expression is modified by in vitro Oxygen Levels and HIF-1a
- Cytokine Storm Interleukins, like IL-1 and IL-6, are regulated by Hypoxia and HIF Signaling
- Room Air Oxygen adds Artifact to in vitro Toxicity Assays in Airway Cells
- In vitro O2 Levels affect Oxidative Stress Response to common COVID Treatments such as Acetaminophen.
To complement cell-based research, scientists use animal models to gain further insight. In vivo hypoxic (or hyperoxic) exposures provide an understanding about coronavirus disease progression or to simulate ventilator-induced injury. Therapeutic models with nitric oxide and carbon dioxide (hypercapnia) are useful for exploring potential COVID-19 treatment options.
Browse 39 Market Data Tables and 28 Figures spread through 193 Pages and in-depth TOC on “Hypoxia Chamber Market”- Global Forecast to 2027, By Type (84 x 35 mm Plates, 27 x 60 mm Plates, 12 x 100 mm Plates, 12 x 96-well Plates, and 18 x 25 cm2 Flasks), By Application (Cell Culture Imaging, Drug Discovery, and Others), By End User (Biopharmaceutical Companies, Clinical Laboratories, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)"
To know the latest trends and insights prevalent in the global hypoxia chamber market, click the link below:
https://www.coherentmarketinsights.com/market-insight/hypoxia-chamber-market-4325
Key players operating in the market are focusing on clinical awareness about the oxygen therapy, which is expected to drive the market growth during the forecast period. For instance, in October 2020, Sechrist Veterinary Health, a manufacturer of Hyperbaric Oxygen Therapy chambers for veterinary specific applications, launched a Clinical Advisory Board to help raise clinical awareness and extend the benefits of hyperbaric oxygen therapy to the veterinary medical community. The Clinical Advisory Board for Veterinary Medical Affairs will consist of independent thought leaders in the veterinary medical community with a shared passion for advancing Hyperbaric Oxygen Therapy as a clinically proven modality. One of the first items on the agenda will lead to development of clinical research in specific applications such as traumatic wounds and pancreatitis, where it can help with the reduction of inflammation and decrease the potential for hypoxia.
Key Takeaways of the Global Hypoxia Chamber Market:
- The global hypoxia chamber market is expected to exhibit a CAGR of 7.7% during the forecast period, owing to adoption of expansion strategies by market players. For instance, in May 2017, AHA Hyperbarics GmbH, announced the launch of its subsidiary AHA Hyperbarics Australia Pty Ltd, in Australia, in order to expand the company’s business and product offerings.
- Among application, cell culture imaging segment is accounted for largest market share in 2020, owing to increasing research and development activities for the development of innovative hypoxia therapy.
- Key players operating in the global hypoxia chamber market are Baker, STEMCELL Technologies Inc, BioSpherix Ltd, Plas-Labs, HypOxygen, Coy Labs, Oxford Optronix Ltd, Scintica Instrumentation Inc., CytoSMART Technologies B.V.
